Abstract
Aim to find new compounds with stronger anticonvulsant activity and lower neurotoxicity, a novel series of 6-substituted-pyrido[3,2-d]pyridazine derivatives was synthesized using furo[3,4-b]pyridine-5,7-dione as the starting material. We evaluated their anticonvulsant activity and neurotoxicity using by maximal electroshock (MES) and rotarod neurotoxicity (TOX) tests. The results showed that N-m-chlorophenyl-[1,2,4]triazolo- [4,3-b]-pyrido[3,2- d]pyridazin-6-amine (3) was the most potent anticonvulsant, with ED50 value of 13.6 mg/kg and protective index ( PI = TD50/ED50) values of 7.2 in the MES test. Compound N-m-chlorophenyltetriazolo[5,1-b]-pyrido[3,2-d]pyridazin-6-amine (19), exhibited significant anticonvulsant activity in maximal electroshock test with PI value of 13.4, which was safer than marketed drug carbamazepine.
Keywords: Pyrido[3, 2-d]pyridazine, anticonvulsant, maximal electroshock, neurotoxicity.
Graphical Abstract
Medicinal Chemistry
Title:Design, Synthesis of 6-Substituted-pyrido[3,2-d]pyridazine Derivatives with Anticonvulsant Activity
Volume: 11 Issue: 6
Author(s): Zheng-Qi Dong, Xiao-Mei Liu, Cheng-Xi Wei and Zhe-Shan Quan
Affiliation:
Keywords: Pyrido[3, 2-d]pyridazine, anticonvulsant, maximal electroshock, neurotoxicity.
Abstract: Aim to find new compounds with stronger anticonvulsant activity and lower neurotoxicity, a novel series of 6-substituted-pyrido[3,2-d]pyridazine derivatives was synthesized using furo[3,4-b]pyridine-5,7-dione as the starting material. We evaluated their anticonvulsant activity and neurotoxicity using by maximal electroshock (MES) and rotarod neurotoxicity (TOX) tests. The results showed that N-m-chlorophenyl-[1,2,4]triazolo- [4,3-b]-pyrido[3,2- d]pyridazin-6-amine (3) was the most potent anticonvulsant, with ED50 value of 13.6 mg/kg and protective index ( PI = TD50/ED50) values of 7.2 in the MES test. Compound N-m-chlorophenyltetriazolo[5,1-b]-pyrido[3,2-d]pyridazin-6-amine (19), exhibited significant anticonvulsant activity in maximal electroshock test with PI value of 13.4, which was safer than marketed drug carbamazepine.
Export Options
About this article
Cite this article as:
Dong Zheng-Qi, Liu Xiao-Mei, Wei Cheng-Xi and Quan Zhe-Shan, Design, Synthesis of 6-Substituted-pyrido[3,2-d]pyridazine Derivatives with Anticonvulsant Activity, Medicinal Chemistry 2015; 11 (6) . https://dx.doi.org/10.2174/1573406411666150313152925
DOI https://dx.doi.org/10.2174/1573406411666150313152925 |
Print ISSN 1573-4064 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6638 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Editorial (Thematic Issue: Mitochondrial Biogenesis: Pharmacological Approaches)
Current Pharmaceutical Design Liverworts-Potential Source of Medicinal Compounds
Current Pharmaceutical Design Automated Planar Electrode Electrophysiology in Drug Discovery: Examples of the Use of QPatch in Basic Characterization and High Content Screening on Nav, KCa2.3, and Kv11.1 Channels
Combinatorial Chemistry & High Throughput Screening The Role of Blood-Brain Barrier Transporters in Pathophysiology and Pharmacotherapy of Stroke
Current Pharmaceutical Design Therapeutic Potential of Group III Metabotropic Glutamate Receptors
Current Medicinal Chemistry Stereoselective Interactions Between Local Anesthetics and Cardiac K+ Channels
Drug Design Reviews - Online (Discontinued) Editorial [Hot topic:VIP and PACAP: Novel Approaches to Brain Functions and Neuroprotection (Executive Guest Editors: Seiji Shioda and Illana Gozes)]
Current Pharmaceutical Design Metabotropic Glutamate Receptors in the Control of Mood Disorders
CNS & Neurological Disorders - Drug Targets PET with Non-Standard Nuclides
Current Topics in Medicinal Chemistry SPECT Radiopharmaceuticals for Dementia
Current Radiopharmaceuticals Tau Pathology and Future Therapeutics
Current Alzheimer Research New Prospects for the Drug Treatment of Generalized Anxiety Disorder — A Systematic Review
Current Drug Therapy Association of Genetic Polymorphisms of CYP2C9 and VKORC1 with Bleeding Following Warfarin: A Case-Control Study
Current Clinical Pharmacology Enantiopure 1,2,3-Triazolyl-β-amino Acids via Click Cycloaddition Reaction on Racemic Alkynyl Precursors Followed by Separation of Stereoisomers
Current Topics in Medicinal Chemistry Glutamate as a Modulator of Embryonic and Adult Neurogenesis
Current Topics in Medicinal Chemistry Role of Biotransformation in Conceptal Toxicity of Drugs and Other Chemicals
Current Pharmaceutical Design CNS Drug Development – Lost in Translation?
Mini-Reviews in Medicinal Chemistry Metabotropic GABAB Receptors New Challenges in Drug Design
Current Medicinal Chemistry - Central Nervous System Agents An EJC Factor RBM8a Regulates Anxiety Behaviors
Current Molecular Medicine On the Involvement of H2S in Nitroso Signaling and Other Mechanisms of H2S Action
Current Pharmaceutical Biotechnology